SI2207550T1 - Tetrahidrokinolinski derivati za zdravljenje posttravmatske stresne motnje - Google Patents

Tetrahidrokinolinski derivati za zdravljenje posttravmatske stresne motnje

Info

Publication number
SI2207550T1
SI2207550T1 SI200831152T SI200831152T SI2207550T1 SI 2207550 T1 SI2207550 T1 SI 2207550T1 SI 200831152 T SI200831152 T SI 200831152T SI 200831152 T SI200831152 T SI 200831152T SI 2207550 T1 SI2207550 T1 SI 2207550T1
Authority
SI
Slovenia
Prior art keywords
traumatic stress
stress disorders
treating post
tetrahydroquinoline derivatives
tetrahydroquinoline
Prior art date
Application number
SI200831152T
Other languages
English (en)
Inventor
Francois Jenck
Original Assignee
Actelion Pharmaceuticals Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40467356&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2207550(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actelion Pharmaceuticals Ltd. filed Critical Actelion Pharmaceuticals Ltd.
Publication of SI2207550T1 publication Critical patent/SI2207550T1/sl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
SI200831152T 2007-10-10 2008-10-09 Tetrahidrokinolinski derivati za zdravljenje posttravmatske stresne motnje SI2207550T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IB2007054130 2007-10-10
EP08807937.1A EP2207550B1 (en) 2007-10-10 2008-10-09 Tetrahydroquinoline derivatives for treating post-traumatic stress disorders
PCT/IB2008/054138 WO2009047723A2 (en) 2007-10-10 2008-10-09 Tetrahydroquinoline derivatives for treating post-traumatic stress disorders

Publications (1)

Publication Number Publication Date
SI2207550T1 true SI2207550T1 (sl) 2014-03-31

Family

ID=40467356

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200831152T SI2207550T1 (sl) 2007-10-10 2008-10-09 Tetrahidrokinolinski derivati za zdravljenje posttravmatske stresne motnje

Country Status (28)

Country Link
US (1) US9532985B2 (sl)
EP (1) EP2207550B1 (sl)
JP (1) JP5883222B2 (sl)
KR (1) KR101733247B1 (sl)
CN (1) CN101820878B (sl)
AR (1) AR068768A1 (sl)
AU (1) AU2008309194B2 (sl)
BR (1) BRPI0818617A2 (sl)
CA (1) CA2699504C (sl)
CY (1) CY1114799T1 (sl)
DK (1) DK2207550T3 (sl)
EA (1) EA017443B1 (sl)
ES (1) ES2444418T3 (sl)
HK (1) HK1145440A1 (sl)
HR (1) HRP20140214T1 (sl)
IL (1) IL204838A (sl)
MA (1) MA31800B1 (sl)
MX (1) MX2010003711A (sl)
MY (1) MY153044A (sl)
NZ (1) NZ585086A (sl)
PE (1) PE20091010A1 (sl)
PL (1) PL2207550T3 (sl)
PT (1) PT2207550E (sl)
SI (1) SI2207550T1 (sl)
TW (1) TWI428129B (sl)
UA (1) UA99150C2 (sl)
WO (1) WO2009047723A2 (sl)
ZA (1) ZA201003251B (sl)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010513466A (ja) 2006-12-22 2010-04-30 アクテリオン ファーマシューティカルズ リミテッド 5,6,7,8−テトラヒドロ−イミダゾ[1,5−a]ピラジン誘導体
CN102076694A (zh) 2008-06-25 2011-05-25 埃科特莱茵药品有限公司 5,6,7,8-四氢-咪唑并[1,5-a]吡嗪化合物
EP2402322A1 (en) 2010-07-02 2012-01-04 Actelion Pharmaceuticals Ltd. 1,2,3,4-tetrahydroisoquinoline derivative and its use as orexin receptor antagonist
JP5744203B2 (ja) 2010-08-24 2015-07-08 アクテリオン ファーマシューティカルズ リミテッドActelion Pharmaceuticals Ltd オレキシン受容体拮抗薬としてのプロリンスルフォンアミド誘導体
PT2626350E (pt) 2010-09-22 2015-08-03 Eisai R&D Man Co Ltd Composto de ciclopropano
US9242970B2 (en) 2010-11-10 2016-01-26 Actelion Pharmaceuticals Ltd. Lactam derivatives useful as orexin receptor antagonists
WO2012085852A1 (en) 2010-12-22 2012-06-28 Actelion Pharmaceuticals Ltd 3,8-diaza-bicyclo[4.2.0]oct-8-yl amides
ES2541531T3 (es) 2011-02-18 2015-07-21 Actelion Pharmaceuticals Ltd. Nuevos derivados de pirazol e imidazol útiles como antagonistas de orexina
WO2012114252A1 (en) 2011-02-21 2012-08-30 Actelion Pharmaceuticals Ltd Novel indole and pyrrolopyridine amides
WO2013050938A1 (en) 2011-10-04 2013-04-11 Actelion Pharmaceuticals Ltd 3,7-diazabicyclo[3.3.1]nonane and 9-oxa-3,7-diazabicyclo[3.3.1]nonane derivatives
AR088692A1 (es) 2011-11-08 2014-06-25 Actelion Pharmaceuticals Ltd Derivados de 2-(1,2,3-triazol-2-il)benzamina y 3-(1,2,3-triazol-2-il)picolinamida
DK2855453T3 (en) 2012-06-04 2017-02-06 Actelion Pharmaceuticals Ltd Benzimidazol-proline derivatives
BR112015007516A2 (pt) 2012-10-10 2017-07-04 Actelion Pharmaceuticals Ltd antagonistas do receptor de orexina que são derivados de [orto bi-(hetero-)aril]-[2-(meta bi-(hetero-)aril)- pirrolidin-1-il]-metanona
EP2970241A1 (en) 2013-03-12 2016-01-20 Actelion Pharmaceuticals Ltd. Azetidine amide derivatives as orexin receptor antagonists
UA119151C2 (uk) 2013-12-03 2019-05-10 Ідорсія Фармасьютікалз Лтд КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА
MX364208B (es) 2013-12-03 2019-04-16 Idorsia Pharmaceuticals Ltd Forma cristalina de (s)-(2-(6-cloro)-7-metil-1h-benzo[d]imidazol-2 -il)-2-metilpirrolidin-1-il) (5-metoxi-2-(2h-1,2,3-triazol-2-il)fe nil) metanona y su uso como antagonistas de receptor de orexina.
KR102330133B1 (ko) 2013-12-04 2021-11-23 이도르시아 파마슈티컬스 리미티드 벤즈이미다졸-프롤린 유도체의 용도
CN107810006B (zh) 2014-10-23 2021-03-30 卫材R&D管理有限公司 用于治疗失眠的组合物
CN115710250A (zh) * 2017-08-01 2023-02-24 博健制药有限责任公司 一种食欲素受体拮抗剂的晶型及其制备方法和用途
WO2020007964A1 (en) 2018-07-05 2020-01-09 Idorsia Pharmaceuticals Ltd 2-(2-azabicyclo[3.1.0]hexan-1-yl)-1h-benzimidazole derivatives
WO2020007977A1 (en) 2018-07-06 2020-01-09 Idorsia Pharmaceuticals Ltd 7-trifluoromethyl-[1,4]diazepan derivatives
WO2020099511A1 (en) 2018-11-14 2020-05-22 Idorsia Pharmaceuticals Ltd Benzimidazole-2-methyl-morpholine derivatives
WO2023218023A1 (en) 2022-05-13 2023-11-16 Idorsia Pharmaceuticals Ltd Thiazoloaryl-methyl substituted cyclic hydrazine-n-carboxamide derivatives

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02008797A (es) 2000-03-14 2005-09-08 Actelion Pharmaceuticals Ltd Derivados de 1,2,3,4-tetrahidroisoquinolina.
CA2518945A1 (en) * 2003-03-26 2004-10-07 Actelion Pharmaceuticals Ltd. Tetrahydroisoquinolyl acetamide derivatives for use as orexin receptor antagonists
CA2557163C (en) 2004-03-01 2011-08-16 Actelion Pharmaceuticals Ltd Substituted 1,2,3,4-tetrahydroisoquinoline derivatives
US7501395B2 (en) 2005-04-25 2009-03-10 Eisai R & D Management Co., Ltd. Method of screening for antianxiety drugs
BRPI0708913A2 (pt) 2006-03-15 2011-06-14 Actelion Pharmaceuticals Ltd uso de compostos derivados de tetraidroisoquinolina para aumentar a funÇço da memària
EP2402322A1 (en) 2010-07-02 2012-01-04 Actelion Pharmaceuticals Ltd. 1,2,3,4-tetrahydroisoquinoline derivative and its use as orexin receptor antagonist

Also Published As

Publication number Publication date
PT2207550E (pt) 2014-02-07
AU2008309194B2 (en) 2013-10-03
ZA201003251B (en) 2011-07-27
HRP20140214T1 (hr) 2014-04-11
MY153044A (en) 2014-12-31
MA31800B1 (fr) 2010-10-01
UA99150C2 (ru) 2012-07-25
JP2011500550A (ja) 2011-01-06
BRPI0818617A2 (pt) 2015-04-07
MX2010003711A (es) 2010-04-30
CN101820878B (zh) 2012-02-01
IL204838A0 (en) 2010-11-30
AR068768A1 (es) 2009-12-02
NZ585086A (en) 2012-03-30
WO2009047723A2 (en) 2009-04-16
CN101820878A (zh) 2010-09-01
IL204838A (en) 2014-09-30
TW200932231A (en) 2009-08-01
CA2699504A1 (en) 2009-04-16
HK1145440A1 (en) 2011-04-21
AU2008309194A1 (en) 2009-04-16
KR20100065203A (ko) 2010-06-15
US20100234420A1 (en) 2010-09-16
EA201000557A1 (ru) 2010-10-29
PE20091010A1 (es) 2009-08-08
US9532985B2 (en) 2017-01-03
EA017443B1 (ru) 2012-12-28
WO2009047723A3 (en) 2009-05-28
ES2444418T3 (es) 2014-02-25
JP5883222B2 (ja) 2016-03-09
KR101733247B1 (ko) 2017-05-08
CY1114799T1 (el) 2016-12-14
CA2699504C (en) 2015-11-24
EP2207550A2 (en) 2010-07-21
TWI428129B (zh) 2014-03-01
DK2207550T3 (da) 2014-01-27
EP2207550B1 (en) 2013-12-11
PL2207550T3 (pl) 2014-05-30

Similar Documents

Publication Publication Date Title
HK1145440A1 (en) Tetrahydroquinoline derivatives for treating post-traumatic stress disorders
HK1212883A1 (zh) 治療眼部疾病的方法
IL241791A0 (en) Historical use of 3,1-diphenylprop-2-en-1-one for the treatment of liver disorders
EP2170309A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF DISEASES
EP2083857A4 (en) METHOD FOR TREATING INTERFERENCE IN CONNECTION WITH MICA
GB0819399D0 (en) Amine derivative compounds for treating ophthalic diseases and disorders
HK1158172A1 (en) Compounds for treating ophthalmic diseases and disorders
WO2010144865A9 (en) Methods for treating gastrointestinal disorders
GB2467710B (en) Methods for treating social disorders
GB2466912B (en) Compositions and methods for treating lysosomal disorders
EP2323681A4 (en) METHODS OF TREATING VIRAL CONDITIONS
WO2011044264A9 (en) Pyrrolopyrazoles for treating cns disorders
EP2142206A4 (en) METHOD FOR THE TREATMENT OF ISCHEMIC ILLNESSES
GB0915259D0 (en) Sulphur-linked compounds for treating ophthalmic diseases and disorders
EP2331097A4 (en) METHOD FOR TREATING CNS DISEASES
EP2120994A4 (en) METHOD AND COMPOSITIONS FOR TREATING HYPOGLYKEMIC CONDITIONS
EP2219650A4 (en) COMPOSITIONS AND METHODS FOR TREATING FIBROPROLIFERATIVE DISORDERS
IL207906A0 (en) Treatment for ocular-related disorders
ZA200801796B (en) Methods for treating substance-related disorders
AU2008901029A0 (en) Methods for treating neurological disorders